GSK's vaccine against respiratory syncytial virus (RSV) is one of ... with the final results of Pfizer's study and as the data from both studies is subjected to scrutiny. The two companies say ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

Far fewer babies had severe cases of the respiratory illness RSV, in a winter in which a new monoclonal and vaccine became ...

The case revolved around whether texts between a top official and a drug company executive counted as a public record that ...

(Reuters) -Infant hospitalizations due to respiratory syncytial virus (RSV) infections in the United States dropped as much ...

says pediatrician Most RSV infections are in babies less than 1 year old. But protection remains out of reach for many "When you look at where this vaccine immunization has been used, there's an ...

and the other was giving an RSV vaccine to women between 32 weeks and 36 weeks of pregnancy. That effort is probably one explanation for the improvement, said Dr. Amanda Williams, interim chief ...

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...